Investor Presentation H1 2023
125
Investor presentation
First six months of 2023
Region China at a glance.
Region China
Million
Diabetes trend
DKK
billion
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
First half of
2023
Sales
(mDKK)
Growth²
200
6%
14%
160
Injectable GLP-13
3,051
95%
50
30
100%
RybelsusⓇ
67
204%
GLP-1
91.6%1
80%
Total GLP-1
3,118
97%
120
20
20
Insulin
Total insulin4
4,783
-11%
2.4%1
60%
175
80
164
141
10
Other Diabetes care5
544
-17%
40%
40
40
10
Diabetes care
8,445
11%
9.6%¹
OAD
Obesity care
100
33%
20%
Diabetes & Obesity care
8,545
11%
0
2021
0
0%
2030
2045
May
2018
Population with diabetes
Diabetes growth rate
May
2023
Rare disease?
Total
383
35%
8,928
12%
GLP-1 MS
-Insulin MS
⚫OAD MS
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
Region China covers Mainland China, Taiwan, and Hong Kong
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of May 2023: Novo Nordisk 52%,
Others 48%; Competitor GLP-1 value market shares, as of May 2023: Novo
Nordisk 71% and Others 29% OAD: Oral anti-diabetic; MS: Market Share;
Source: IQVIA MAT, May 2023 value figures
2 At constant exchange rates; 3 Comprises VictozaⓇ and OzempicⓇ; 4
Comprises Tresiba®, XultophyⓇ, Levemir®, NovoMix®, Ryzodeg®, NovoRapidⓇ;
5Comprises Novo NormⓇ and needles; 6Comprises SaxendaⓇ; Comprises
primarily NovoSeven®, Novo Eight® and NorditropinⓇView entire presentation